UroGen Pharma (URGN) is scheduled to report Q1 earnings on May 11, 2026. Analysts estimate EPS of $-0.52 and quarterly revenue of $43.72M.

In the most recent quarter (Q4), UroGen Pharma reported EPS of $-0.54, beating estimates of $-0.57 by 0.05%. Revenue came in at $37.84M, missing the estimate of $38.17M by 0.01%.

UroGen Pharma has beaten EPS estimates in 2 consecutive quarters.

Over the last 4 quarters, UroGen Pharma has averaged an EPS surprise of 0.12% and a revenue surprise of 0.07%.